Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EPS (Weighted Average and Diluted) (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.81 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 211.54% to -$0.81 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.94, a 17.54% increase, with the full-year FY2023 number at -$5.11, up 93.1% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.81 for Q4 2025 at Aytu Biopharma, down from -$0.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.21 in Q1 2025 to a low of -$21.76 in Q3 2021.
  • A 5-year average of -$2.79 and a median of -$0.81 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 6117.14% in 2021, then skyrocketed 126.58% in 2025.
  • Aytu Biopharma's EPS (Weighted Average and Diluted) stood at -$8.74 in 2021, then soared by 73.23% to -$2.34 in 2022, then soared by 104.7% to $0.11 in 2023, then crashed by 336.36% to -$0.26 in 2024, then plummeted by 211.54% to -$0.81 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EPS (Weighted Average and Diluted) are -$0.81 (Q4 2025), -$0.08 (Q3 2025), and $0.21 (Q1 2025).